Search
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalHaemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII. … Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot.
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalGenerally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].
Pentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePhendimetrazine
go.drugbank.com/drugs/DB01579ApprovedIllicitPhendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnAbciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. … Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules
Vortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalreceptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. … It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.
Acrivastine
go.drugbank.com/drugs/DB09488ApprovedAcrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. … Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever.
Mixtures: Semprex-D, Semprex DTofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46108] Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP, -(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R